Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ulrike K. Buchwald, Charles P. Andrews, John Ervin, James T. Peterson, Gretchen M. Tamms, David Krupa, Patrick Ajiboye, Lucy Roalfe, Andrea L. Krick, Tina M. Sterling, Meihua Wang, Jason C. Martin, Jon E. Stek, Melvin A. Kohn, Temitope Folaranmi, Chitrananda Abeygunawardana, Jonathan Hartzel & Luwy K. Musey. (2021) Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older. Human Vaccines & Immunotherapeutics 17:8, pages 2678-2690.
Read now
Read now
Christine Juergens, James Trammel, Yasuko Shoji, Scott Patterson, Wendy Watson, Chris Webber, William C. Gruber, Daniel A. Scott & Beate Schmoele-Thoma. (2018) Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations. Human Vaccines & Immunotherapeutics 14:8, pages 1948-1956.
Read now
Read now
Lander Willem, Adriaan Blommaert, Germaine Hanquet, Nancy Thiry, Joke Bilcke, Heidi Theeten, Jan Verhaegen, Herman Goossens & Philippe Beutels. (2018) Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium. Human Vaccines & Immunotherapeutics 14:5, pages 1218-1229.
Read now
Read now
Masanari Shiramoto, Ryuzo Hanada, Christine Juergens, Yasuko Shoji, Mizuki Yoshida, Barry Ballan, David Cooper, William C Gruber, Daniel A Scott & Beate Schmoele-Thoma. (2015) Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Human Vaccines & Immunotherapeutics 11:9, pages 2198-2206.
Read now
Read now
Articles from other publishers (24)
Miwako Kobayashi, Tamara Pilishvili, Jennifer L. Farrar, Andrew J. Leidner, Ryan Gierke, Namrata Prasad, Pedro Moro, Doug Campos-Outcalt, Rebecca L. Morgan, Sarah S. Long, Katherine A. Poehling & Adam L. Cohen. (2023) Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR. Recommendations and Reports 72:3, pages 1-39.
Crossref
Crossref
Heather Platt, Tosin Omole, Jose Cardona, Neil J Fraser, Richard A Mularski, Charles Andrews, Nizar Daboul, Nancy Gallagher, Aditi Sapre, Jianing Li, Adam Polis, Doreen Fernsler, Gretchen Tamms, Weifeng Xu, Rocio Murphy, Julie Skinner, Joseph Joyce & Luwy Musey. (2023) Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. The Lancet Infectious Diseases 23:2, pages 233-246.
Crossref
Crossref
Etsuro Nanishi, Asimenia Angelidou, Chloe Rotman, David J Dowling, Ofer Levy & Al Ozonoff. (2022) Precision Vaccine Adjuvants for Older Adults: A Scoping Review. Clinical Infectious Diseases 75:Supplement_1, pages S72-S80.
Crossref
Crossref
Leela R. L. Davies, Deniz Cizmeci, Wenyue Guo, Corinne LuedemannRonika Alexander-Parrish, Lindsay GrantRaul IsturizChristian Theilacker, Luis Jodar, Bradford D. GessnerGalit Alter. (2022)
Polysaccharide and conjugate vaccines to
Streptococcus pneumoniae
generate distinct humoral responses
. Science Translational Medicine 14:656.
Crossref
Crossref
Chih-Kuang Liang, Wei-Ju Lee, Li-Ning Peng, Lin-Chieh Meng, Fei-Yuan Hsiao & Liang-Kung Chen. (2022) COVID-19 Vaccines in Older Adults. Clinics in Geriatric Medicine 38:3, pages 605-620.
Crossref
Crossref
Gurunadh R. Chichili, Ronald Smulders, Vicki Santos, Beth Cywin, Laura Kovanda, Charles Van Sant, Frank Malinoski, Shite Sebastian, George Siber & Richard Malley. (2022) Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years. Vaccine 40:31, pages 4190-4198.
Crossref
Crossref
Sara Russo Krauss, Marija Barbateskovic, Sarah Louise Klingenberg, Snezana Djurisic, Sesilje Bondo Petersen, Mette Kenfelt, De Zhao Kong, Janus C Jakobsen & Christian Gluud. (2022) Aluminium adjuvants versus placebo or no intervention in vaccine randomised clinical trials: a systematic review with meta-analysis and Trial Sequential Analysis. BMJ Open 12:6, pages e058795.
Crossref
Crossref
Amr Shaaban Hanafy, Waseem M. Seleem & Hany A. Elkattawy. (2022) Potential impact of combined influenza and pneumococcal vaccines on the severity of respiratory illness in COVID-19 infection among type 2 diabetic patients. Clinical and Experimental Medicine.
Crossref
Crossref
Jeremy A. Duke, Amy V. Paschall, Lloyd S. Robinson, Cory J. Knoot, Evgeny Vinogradov, Nichollas E. Scott, Mario F. Feldman, Fikri Y. Avci & Christian M. Harding. (2021)
Development and Immunogenicity of a Prototype Multivalent Group B
Streptococcus
Bioconjugate Vaccine
. ACS Infectious Diseases 7:11, pages 3111-3123.
Crossref
Crossref
Donald Hurley, Carl Griffin, Mariano YoungJrJr, Daniel A Scott, Michael W Pride, Ingrid L Scully, John Ginis, Joseph Severs, Kathrin U Jansen, William C Gruber & Wendy Watson. (2021) Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. Clinical Infectious Diseases 73:7, pages e1489-e1497.
Crossref
Crossref
Courtney Gidengil, Matthew Bidwell Goetz, Sydne Newberry, Margaret Maglione, Owen Hall, Jody Larkin, Aneesa Motala & Susanne Hempel. (2021) Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. Vaccine 39:28, pages 3696-3716.
Crossref
Crossref
Christopher Mensch, Ramesh Chintala, Denise Nawrocki, Jeffrey T. Blue & Akhilesh Bhambhani. (2021) Enabling Lyophilized Pneumococcal Conjugate Vaccines Through Formulation Design and Excipient Selection Suitable for A Multivalent Adjuvanted Vaccine. Journal of Pharmaceutical Sciences 110:1, pages 97-107.
Crossref
Crossref
Jairam Meena, Robin Kumar, Mamta Singh, Anees Ahmed & Amulya Kumar Panda. (2020) Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 152, pages 270-281.
Crossref
Crossref
Ermias Jirru, Stefi Lee, Rebecca Harris, Jianjun Yang, Soo Jung Cho & Heather Stout-Delgado. (2020) Impact of Influenza on Pneumococcal Vaccine Effectiveness during Streptococcus pneumoniae Infection in Aged Murine Lung. Vaccines 8:2, pages 298.
Crossref
Crossref
Almea Matanock, Grace Lee, Ryan Gierke, Miwako Kobayashi, Andrew Leidner & Tamara Pilishvili. (2019) Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR. Morbidity and Mortality Weekly Report 68:46, pages 1069-1075.
Crossref
Crossref
Nirma Khatri Vadlamudi, Kamalpreet Parhar, Kim Lorenzo Altre Malana, Amy Kang & Fawziah Marra. (2019) Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis. Vaccine 37:8, pages 1021-1029.
Crossref
Crossref
James P Phipps & Karen M Haas. (2019) An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses. The Journal of Infectious Diseases 219:2, pages 323-334.
Crossref
Crossref
Fawziah Marra & Nirma Khatri Vadlamudi. (2019) Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults. Aging and disease 10:2, pages 404.
Crossref
Crossref
Anita Jeyakumar, Rodolpho E. Bégué, Yu Jiang & Brian J. McKinnon. (2018) Cochlear implant provider awareness of vaccination guidelines. The Laryngoscope 128:9, pages 2145-2152.
Crossref
Crossref
C.T. Rieger, B. Liss, S. Mellinghoff, D. Buchheidt, O.A. Cornely, G. Egerer, W.J. Heinz, M. Hentrich, G. Maschmeyer, K. Mayer, M. Sandherr, G. Silling, A. Ullmann, M.J.G.T. Vehreschild, M. von Lilienfeld-Toal, H.H. Wolf & N. Lehners. (2018) Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Annals of Oncology 29:6, pages 1354-1365.
Crossref
Crossref
Bin Jia, Lisa K. McNeil, Christopher D. Dupont, Konstantinos Tsioris, Rachel M. Barry, Ingrid L. Scully, Adebola O. Ogunniyi, Christopher Gonzalez, Michael W. Pride, Todd M. Gierahn, Paul A. Liberator, Kathrin U. Jansen & J. Christopher Love. (2017) Longitudinal multiparameter single-cell analysis of macaques immunized with pneumococcal protein-conjugated or unconjugated polysaccharide vaccines reveals distinct antigen specific memory B cell repertoires. PLOS ONE 12:9, pages e0183738.
Crossref
Crossref
G. Falkenhorst, C. Remschmidt, T. Harder, O. Wichmann, S. Glodny, E. Hummers-Pradier, T. Ledig & C. Bogdan. (2016) Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 59:12, pages 1623-1657.
Crossref
Crossref
Andrew J. Ullmann, Martin Schmidt-Hieber, Hartmut Bertz, Werner J. Heinz, Michael Kiehl, William Krüger, Sabine Mousset, Stefan Neuburger, Silke Neumann, Olaf Penack, Gerda Silling, Jörg Janne Vehreschild, Hermann Einsele & Georg Maschmeyer. (2016) Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Annals of Hematology 95:9, pages 1435-1455.
Crossref
Crossref
Adrian Gillissen. (2015) 13-valenter Impfstoff schützt auch Ältere gut. Pneumo News 7:3, pages 8-9.
Crossref
Crossref